Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AZD4144 in Healthy Participants
NCT06122714Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD4144 in atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) (7 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs). Started Nov 2023; status: completed.
02
Drugs
AZD4144
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06122714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122714.